Relay Therapeutics, Inc. RLAY Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $15.36M+53.5% | $10.01M-60.8% | $25.55M+1,750% | $1.38M-54.4% | ||
| $261.38M-18.1% | $319.09M-3.3% | $330.02M+34.0% | $246.36M+42.7% | ||
| $56.71M-26.0% | $76.59M+2.2% | $74.95M+13.6% | $65.98M+15.0% | ||
| $318.09M-16.8% | $382.48M-4.0% | $398.55M+32.6% | $300.66M-18.2% | ||
| -$302.74M+18.7% | -$372.47M+0.1% | -$373M-24.6% | -$299.28M+17.9% | ||
| -1,971.5%+1,751pp | -3,722.1%-2,262pp | -1,460.1%+20,211pp | -21,670.9%-9,631pp | ||
| $26.26M-24.5% | $34.76M+12.0% | $31.03M+254% | $8.77M+961% | ||
| -$276.48M+18.1% | -$337.71M+1.2% | -$341.97M-17.7% | -$290.51M+20.2% | ||
| -1,800.5%+1,574pp | -3,374.7%-2,036pp | -1,338.6%+19,698pp | -21,036.1%-9,023pp | ||
| -$1.61+31.8% | -$2.36+15.7% | -$2.80-8.1% | -$2.59+32.7% | ||
| -$299.18M+18.5% | -$367M+0.2% | -$367.73M-24.6% | -$295.15M+18.2% | ||
| -1,948.3%+1,719pp | -3,667.5%-2,228pp | -1,439.4%+19,932pp | -21,371.8%-9,461pp | ||
| -$302.74M+18.7% | -$372.47M+0.1% | -$373M-24.6% | -$299.28M+17.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Relay Therapeutics, Inc.'s revenue?
- Relay Therapeutics, Inc. (RLAY) generated $10.7M in revenue over the trailing twelve months, up 39.0% year over year.
- Is Relay Therapeutics, Inc. profitable?
- Relay Therapeutics, Inc. is not currently profitable: it reported a net loss of $272.7M over the trailing twelve months, a -2554.1% net margin.
- What is Relay Therapeutics, Inc.'s earnings per share?
- Relay Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.56.
- Where does Relay Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Relay Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
